Eflapegrastim
Identifiers | |
---|---|
CAS Number | |
ChemSpider |
|
UNII | |
KEGG |
Eflapegrastim (HM-10460A) is a long acting G-CSF analog developed by Hanmi Pharmaceutical and licensed to Spectrum Pharmaceuticals. It was developed for the treatment of chemotherapy-induced neutropenia.[1]
It is in phase III clinical trials comparing the efficacy to that of pegfilgrastim in patients with breast cancer.[2]
References[]
Categories:
- Experimental cancer drugs